This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Food And Chemical Toxicology Editor-in-Chief, A. Wallace Hayes, Publishes Response To Letters To The Editors

A second concern that has been raised is whether this retraction follows the COPE guidelines. The COPE guidelines were consulted when making this decision. According to the COPE guidelines, "Journal editors should consider retracting a publication if… they have clear evidence that the findings are unreliable, either as a result of misconduct (e.g. data fabrication) or honest error (e.g. miscalculation or experimental error)."(COPE, 2009). The retraction statement could have been clearer, and should have referred to the relevant COPE guidelines. The data are inconclusive, therefore the claim (ie, conclusion) that Roundup Ready maize NK603 and/or the Roundup herbicide have a link to cancer is unreliable. Dr. Séralini deserves the benefit of the doubt that this unreliable conclusion was reached in honest error. The review of the data made it clear that there was no misconduct. However, to be very clear, it is the entire paper, with the claim that there is a definitive link between GMO and cancer that is being retracted. Dr. Séralini has been very vocal that he believes his conclusions are correct. In our analysis, his conclusions cannot be claimed from the data presented in this article.

At this point it is very important to state that the retraction does not reflect or impact the journal's view on GMOs or associated organizations. Our journal would, in fact, very much welcome the opportunity to review follow-up studies that have a greater sample size, a fine-tuned method, and proper controls. We are also actively searching and recruiting people to provide a balance view on this topic to serve on the editorial board.

 Finally, the letters post-retraction have questioned whether an earlier study done by Monsanto received different treatment from our journal. This article was published in 2004, well before I became Editor-in-Chief. However, I take the issue seriously and have reviewed this paper in detail. The Hammond et al. article was a 13 week feeding study performed in rats feed grain from Roundup Ready corn which is tolerant to the herbicide glyphosate (Hammond et al., 2004).  The authors reported the following: "Purina TestDiets formulated Roundup Ready corn grain into rodent diets at levels of 11 and 33% (w/w). The responses of rats fed diets containing Roundup Ready corn grain were compared to that of rats fed diets containing non-transgenic grain (controls). All diets were nutritionally balanced and conformed to Purina Mills, Inc. specifications for Certified Lab Diet 5002. There were 400 rats in the study divided into 10 groups of 20 rats/sex/group. Overall health, body weight, food consumption, clinical pathology parameters (hematology, blood chemistry, urinalysis), organ weights, gross and microscopic appearance of tissues were comparable between groups fed diets containing Roundup Ready and control corn grain…  This study complements extensive agronomic, compositional and farm animal feeding studies with Roundup Ready corn grain, confirming it is as safe and nutritious as existing commercial corn hybrids."  The authors also stated "The study design was adapted from OECD Guideline No. 408 (1981) and the study was reported to have been conducted in general compliance with OECD Good Laboratory Practice (GLP) guidelines at the Metabolism and Safety Evaluation-Newstead, toxicology laboratory."  

In accordance with OECD Guideline No. 408 (OECD, 2009a), the Hammond et al. study was limited to 90 days following and used 20 rats/sex/group, and was conducted in general compliance with OECD Good Laboratory Practice (GLP) guidelines, as previously stated. The Séralini et al. study ran for two (2) years with only 10 rats/sex/group and was reported to be done in a GLP environment according to OECD guidelines (which guideline is not explicitly stated in the paper).   Séralini et al. state that they had "had no reason to settle at first for a carcinogenesis protocol using 50 rats per group," as recommended in OECD Nos. 451 and 453 (guidelines for Carcinogenicity Studies and Combined Chronic Toxicity/Carcinogenicity Studies, respectively)(OECD, 2009a; OECD, 2009b), and instead seem to have opted for 10 rats/sex/group as recommended by OECD No. 408 (guidelines for Repeated Dose 90-day Oral Toxicity Study in Rodents).  While the number of animals used may have been sufficient to reach conclusions regarding oral toxicity, it proved insufficient for conclusions related to the carcinogenicity of the test substances.

In conclusion, FCT has retracted this article because our thorough investigations revealed that its methods were scientifically flawed. The low number of animals, and the strain selected, rendered the conclusions unreliable.  No definitive conclusions could be drawn from the inconclusive data. Therefore, in accordance with both the COPE guidelines and the journal policy, it was necessary to take this action of retracting the article.  

2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,982.59 +22.02 0.13%
S&P 500 1,978.91 +0.57 0.03%
NASDAQ 4,444.9090 -4.6550 -0.10%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs